Elicio (ELTX): Debts to Book Capitalization

Graphic logo of Elicio Therapeutics Inc. (ELTX)

This daily price chart for Elicio Therapeutics (ELTX) reflects the dynamics of a company developing unique antigen delivery methods that minimize market pressure during testing. The business relies on the AMP platform for precise tumor targeting via lymph nodes, with the indicator standing at 1.66. Efficiency is enhanced through the implementation of AI pipelines that automate vaccine analysis, freeing scientists from repetitive operations.

Elicio Therapeutics (ELTX) - Debts to Book Value from 02/21/2024 to 10/28/2026

Elicio Therapeutics Inc. (ELTX) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Chart Elicio Therapeutics|ELTX - Broker Consensus Forecast
- market capitalization data:
Market Capitalization Elicio Therapeutics, Inc|ELTX - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share Elicio Therapeutics|ELTX - Total Stockholders' Equity|Market Value to Book Value Ratio elicio.com|ELTX - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Equity Ratio Elicio Therapeutics|ELTX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Elicio|ELTX - Company Debts|Debt to Book Value Elicio Therapeutics, Inc|ELTX - Long-Term Debt|Company Short-Term Debt Elicio Therapeutics
Analysis of all company metrics:Elicio Therapeutics - ELTX
Core merchandise of Elicio

This indicator measures the extent of the company's reliance on debt relative to the value of its net assets, allowing for a real-time assessment of credit pressure risk. By analyzing the trend of the debt-to-capitalization ratio, an investor determines the financial stability of Elicio Therapeutics (ELTX) required to implement the AMP platform and ensure pricing power when bringing unique anti-tumor vaccines to market.

Who Elicio Therapeutics competes with

CRVS - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Prelude Therapeutics Inc. PRLD